The mixed Phase 3 data (strong hemoglobin and transfusion benefits but missed pain crisis and fatigue endpoints) creates binary regulatory risk ahead of the sNDA review. Traders should watch for FDA acceptance of the accelerated approval filing and any AdCom vote, which will determine whether the anti-hemolytic profile is sufficient for approval without statistical significance on pain crises.
Price Chart
Executive Summary
Agios presented detailed Phase 3 RISE UP data for mitapivat in sickle cell disease at EHA 2026, showing statistically significant hemoglobin response (40.6% vs 2.9% placebo) and a 41.1% relative reduction in transfusion burden. However, the primary endpoint of sickle cell pain crisis reduction did not reach statistical significance, and the fatigue endpoint showed no overall difference versus placebo, creating a mixed clinical profile. The company submitted an sNDA for accelerated approval in May 2026, making this a pivotal regulatory catalyst.
Key Facts
- Hemoglobin response achieved by 40.6% of mitapivat patients vs 2.9% placebo (p<0.0001)
- Annualized sickle cell pain crisis rate reduction did not reach statistical significance
- 41.1% relative reduction in patients requiring transfusions (23.9% mitapivat vs 40.6% placebo)
- 55.9% relative reduction in average red blood cell units transfused per patient
- sNDA for accelerated approval submitted to FDA in May 2026
- No treatment-related deaths; safety profile consistent with prior trials
- Nearly all (174/176) completers opted into open-label extension
Financial Impact
Mitapivat is Agios' lead pipeline asset for sickle cell disease, a large underserved market. Approval could transform revenue potential, but the mixed efficacy data (hemoglobin response positive, pain crises miss) creates regulatory uncertainty. No financial figures provided in the release.
Risk Factors
- FDA may require statistically significant pain crisis reduction for full approval, which was not achieved
- Accelerated approval pathway uncertain given mixed primary endpoint results
- Competition from existing sickle cell therapies (e.g., hydroxyurea, voxelotor, gene therapies)
- Commercial adoption dependent on payer coverage and differentiation from standard of care
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311392 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 144 | $37.19 | awaiting T+60 | — | $36.83 (−0.97%) |
Aug 6, 2026 11w ago | Institutional Cluster | $31.95 | awaiting T+60 | — | $36.83 (+15.27%) |
Jul 30, 2026 12w ago | 8-K | $32.75 $37.00 | ▲ +12.98% | ▲ +10.51% | $36.83 (+12.46%) |
Jul 30, 2026 12w ago | Press Release | $32.75 $37.00 | ▲ +12.98% | ▲ +10.51% | $36.83 (+12.46%) |
Jul 7, 2026 15w ago | Press Release | $44.01 $33.25 | ▼ −24.45% | ▼ −26.44% | $36.83 (−16.31%) |
Jun 29, 2026 17w ago | Press Release | $38.04 $34.97 | ▼ −8.07% | ▼ −12.46% | $36.83 (−3.18%) |
Jun 18, 2026 18w ago | 8-K | $35.10 $32.81 | ▼ −6.52% | ▼ −8.27% | $36.83 (+4.93%) |
Jun 13, 2026 19w ago | Press Release | $31.82 $34.63 | ▲ +8.83% | ▲ +7.83% | $36.83 (+15.74%) |
Jun 1, 2026 21w ago | Press Release | $28.00 $33.90 | ▲ +21.07% | ▲ +19.84% | $36.83 (+31.54%) |
May 29, 2026 21w ago | Press Release | $29.40 $32.64 | ▼ −11.02% | ▼ −9.84% | $36.83 (−25.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers